Cousin Surgery

Who owns Cousin Surgery?

Cousin Surgery is currently owned by Turenne Groupe through Capital Santé 2 (2020 vintage), since 2019. Across its history, Cousin Surgery has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

About Cousin Surgery

Cousin Surgery, formerly Cousin Medical Group, is a Wervicq-Sud, France based medical device company that designs, manufactures and markets implantable devices built from technical textiles, addressing spine surgery, hernia and abdominal wall reinforcement, visceral and digestive surgery, uro-gynaecological indications and adhesion prevention and haemostasis. The group works directly with surgeons on device design and, per its own disclosures, produces around 200,000 implants a year and employs roughly 150 people, generating the large majority of revenue from exports. At its 2019 recapitalisation it reported revenue of about EUR 22 million, close to three-quarters of it from exports, with around 110 staff. Alongside its proprietary implant business it runs Cousin Manufacturing, a contract development and manufacturing arm for high-value textile implants, and Cousin Academy, a surgeon-training programme.

Ownership journey

Cousin Medical Group traces its implantable-device activity to 1995 and grew out of the long-established Cousin technical-textile industry in the north of France. In April 2019 Turenne Groupe took a majority position, investing EUR 10.8 million through its Capital Sante 2 fund with the Nord Capital Investissement and Dalle & Associes teams, while Altur Investissement invested EUR 1.2 million, in a transaction that reorganised the shareholding and bought out the founding family investors. The incumbent management, led by Francois Tortel and Francois Henin, reinvested alongside the new financial backers. Turenne Groupe and Altur Investissement remain current shareholders of the group, now branded Cousin Surgery, and no exit or secondary sale has been recorded.

Under PE ownership

The 2019 investment was framed as growth and capital-reorganisation funding for the group's spine and visceral franchises, after which the business was rebranded from Cousin Medical Group to Cousin Surgery. In May 2023 it completed the acquisition of PlantTec Medical, a German specialist whose plant-based 4DRYFIELD haemostatic and anti-adhesion product holds a worldwide-first CE marking and is sold in more than 30 countries, a build-up financed by Capital Sante 2, Altur Investissement and their co-investors together with management. The deal added a haemostasis and adhesion-prevention line to the textile-implant portfolio and broadened the group's international reach. Reported headcount has grown from roughly 110 at entry toward about 150, and the company continues to run clinical trials and surgeon-training programmes to support adoption of its devices.